Progressive Disease Does Not Impact Hrqol In Patients Receiving Nivolumab For The Treatment Of Unresectable Or Metastatic Melanoma
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1271
https://www.valueinhealthjournal.com/article/S1098-3015(15)03347-1/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
771
First Page :
A475
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03347-1&doi=10.1016/j.jval.2015.09.1271